Dear Editor,
Since December 2019, a novel coronavirus (SARS‐CoV‐2) was reported in Wuhan, Hubei Province, China, causing severe acute respiratory syndrome, particularly in the elderly population, with quick spread worldwide. Clinical presentation can range from no symptoms to fever, dry cough, fatigue, sore throat, until severe pneumonia and death. It remains unknown to what extent SARS‐CoV‐2 infection impacts chronic inflammatory skin diseases, such as psoriasis, and their treatment. In particular, there is no clear evidence if systemic treatment such as biologic agents can increase the risk of infection or worsen the course of COVID‐19. 1 We report here our experience with COVID‐19 infection in psoriatic patients treated with biologic agents. One‐hundred thirty‐nine patients in biologic therapy for chronic plaques psoriasis, followed at our Hospital in Lecco, Northern Italy (the most coronavirus affected area in Italy), were reviewed for evidence of COVID‐19 infection. Clinical data, aimed at the detection of SARS‐CoV‐2 related symptoms, were obtained as follows: 40% of the patients were directly examined in a scheduled visit from March 9th to May 6th; the other patients were interviewed by phone in the period from May 4th to 6th. Clinical history and comorbidities were retrieved from medical records. Five patients, all of whom were in treatment for more than a year, developed symptoms consistent with SARS‐CoV‐2 infection (Table 1). Three patients developed fever and flu‐like symptoms, and two developed pneumonia. A nasopharyngeal swab gave a positive result for SARS‐CoV‐19 in three patients, whilst two patients had no specific diagnostic tests but had symptoms highly suggestive of SARS‐CoV‐2 infection and reported contact with positive COVID‐19 relatives. The mean age was 51.8 years (range 36–72). Hospitalization was necessary for one patient, diagnosed with interstitial pneumonia, receiving therapy with infliximab. In the specific case, the patient was treated with mask oxygen therapy, azithromycin, hydroxychloroquine, lopinavir, and enoxaparin. The patient was discharged after 2 weeks. Biologic therapies are engineered to target specific mediators of inflammation, such as tumor necrosis factor‐alpha, interleukin 17, and interleukin 23, therefore they have the potential to impact both on the risk of viral infection and on the risk of more severe disease. 2 The incidence of SARS‐CoV‐2 infection in our psoriatic patients (3.6%) is higher than that of the general population in the Lecco district (0.7%, data as of May 4th from the Italian Ministry of Health), but the small sample investigated does not allow to draw reliable conclusions about any increased risk of infection. In our series, biologic therapy does not seem to worsen the severity of COVID‐19, since all our patients had a mild course of the disease with complete resolution in 2–3 weeks. This finding is consistent with previous observations in rheumatologic patients. 3 A hypothesis could be that biologic therapies would lessen the overall inflammatory response to SARS‐CoV‐2. In conclusion, the lack of scientific data, at the moment, does not enable us to set reliable guidelines to help with patients in immunomodulating therapy in the COVID‐19 era. 4 All in all, our limited experience suggests that biologic therapies, probably because of their mechanism of action, do not seem to increase the severity of COVID‐19 nor the risk of complications. Additional data are needed to confirm this preliminary observation.
Table 1.
Characteristics of patients
| Patient | Gender | Age | Covid‐19 swab | Manifestations | Biologic therapy | Start of therapy | Comorbidity | Hospitalization |
|---|---|---|---|---|---|---|---|---|
| 1 | F | 63 | + | Interstitial pneumonia | Etanercept | 2008 | — | ‐ |
| 2 | F | 43 | + | Fever, fatigue, ageusia, anosmia | Adalimumab | 2015 | Psoriatic arthritis | ‐ |
| 3 | M | 45 | Not performed | Fever, fatigue, dry cough | Ustekinumab | 2018 | — | ‐ |
| 4 | F | 36 | Not performed | Fever, fatigue, dry cough | Ixekizumab | 2018 | Psoriatic arthritis | ‐ |
| 5 | M | 72 | + | Interstitial pneumonia | Infliximab | 2013 | Nonalcoholic fatty liver disease, hypertension, obesity (BMI 35) | + |
Abbreviations: F, female; M, male; +, positive; BMI, body mass index.
Confict of interest: Davide Strippoli has been a consultant and/or speaker for Abbvie, Celgene, Janssen, Eli Lilly, Novartis, Pfizer. Tania Barbagallo has been a consultant and/or speaker for Novartis, Celgene. Francesca Prestinari has been a consultant and/or speaker for Novartis, Leo‐Pharma. Giuseppe Russo has nothing to declare. Fabrizio Fantini has nothing to declare.
Funding source: None.
References
- 1. Bashyam AM, Feldman SR. Should patients stop their biologic treatment during the COVID‐19 pandemic. J Dermatolog Treat 2020; 19: 1–2. [DOI] [PubMed] [Google Scholar]
- 2. D'Antiga L. Coronaviruses ad immunosuppressed patients: the facts during the third epidemic. Liver Transpl 2020. (Epub ahead of print). [DOI] [PubMed] [Google Scholar]
- 3. Monti S, Balduzzi S, Delvino P, et al. Clinical course of COVID‐19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020; 79: 667–668. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Brownstone ND, Thibodeaux Q, Reddy VD, et al. Novel coronavirus disease (COVID‐19) and biologic therapy in psoriasis: infection risk and patient counseling in uncertain times. Dermatol Ther 2020; 10: 339–349. [DOI] [PMC free article] [PubMed] [Google Scholar]